Toronto Dominion Bank purchased a new position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 174,035 shares of the health services provider's stock, valued at approximately $15,801,000. Toronto Dominion Bank owned about 0.53% of Amedisys as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of AMED. Trexquant Investment LP raised its stake in Amedisys by 1,317.8% during the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock valued at $7,964,000 after purchasing an additional 81,532 shares during the last quarter. ABC Arbitrage SA acquired a new position in shares of Amedisys during the fourth quarter valued at about $2,522,000. Schonfeld Strategic Advisors LLC lifted its stake in shares of Amedisys by 17.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 4,500 shares of the health services provider's stock valued at $409,000 after buying an additional 671 shares during the period. Empowered Funds LLC acquired a new stake in Amedisys during the fourth quarter worth about $318,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Amedisys during the fourth quarter worth about $590,000. 94.36% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities analysts have commented on the company. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 price target on shares of Amedisys in a report on Wednesday, April 16th. Stephens restated an "equal weight" rating and issued a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Amedisys presently has an average rating of "Hold" and a consensus target price of $100.75.
View Our Latest Stock Report on Amedisys
Amedisys Stock Down 0.5%
NASDAQ AMED opened at $94.12 on Tuesday. Amedisys, Inc. has a 1-year low of $82.15 and a 1-year high of $98.95. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of 37.35, a PEG ratio of 1.78 and a beta of 0.96. The stock's 50 day moving average is $93.26 and its two-hundred day moving average is $91.60. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.
Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, beating the consensus estimate of $1.13 by $0.12. The business had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Amedisys's quarterly revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.03 EPS. Equities analysts forecast that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.
About Amedisys
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Further Reading
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMED - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
